.jpg?format=webp&width=780)
The study investigated the effects of once-weekly subcutaneous semaglutide, a GLP-1RA, for up to two years in people with T2D in routine clinical practice. The study used data from national registries and included people who redeemed at least one prescription of semaglutide and had two years of follow-up. The results showed that people treated with semaglutide experienced clinically relevant and sustained improvements in glycaemic control after 180, 360, 540, and 720 days, irrespective of former GLP-1RA exposure, comparable with effects observed in clinical studies. These results support the use of semaglutide in routine clinical practice for the long-term management of T2D.
Like
Save
Share